Nanovaccine: A hope to triumph the battle against novel Coronavirus disease 2019 (COVID-19).

Singh, A; Maurya, A; Mishra, G; Awasthi, R; Dua, K; Kulkarni, G

Nanovaccine: A hope to triumph the battle against novel Coronavirus disease 2019 (COVID-19).

Singh, A Maurya, A Mishra, G Awasthi, R Dua, K

Kulkarni, G

Permalink

Publisher:: Bentham Science Publishers Ltd.
Publication Type:: Journal Article
Citation:: Recent patents on nanotechnology, 2021, 15
Issue Date:: 2021-07-20

Closed Access

	Filename	Description	Size
	2nd Awasthi (4) MS.pdf	Accepted version	1.01 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Singh, A
dc.contributor.author	Maurya, A
dc.contributor.author	Mishra, G
dc.contributor.author	Awasthi, R
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Kulkarni, G
dc.date.accessioned	2021-09-19T03:04:45Z
dc.date.available	2021-05-28
dc.date.available	2021-09-19T03:04:45Z
dc.date.issued	2021-07-20
dc.identifier.citation	Recent patents on nanotechnology, 2021, 15
dc.identifier.issn	1872-2105
dc.identifier.issn	2212-4020
dc.identifier.uri	http://hdl.handle.net/10453/150634
dc.description.abstract	<h4>Background</h4>The novel coronavirus 2019 (COVID-19) infection has caused the global emergence of coronavirus in humans during the last 12 months. Till May 11, 2021, the confirmed global COVID-19 cases and deaths reached 158551526 and 3296855, respectively.<h4>Methods</h4>Goblet cells and ciliated cells in the nose act as the initial infection site of SARS-CoV-2. Thus, mucus immunity is important to protect from infection. The outburst of SARS-CoV-2 infection can be halted only when an effective vaccine will be developed.<h4>Results</h4>Globally, over 100 different vaccines are under investigation, including DNA vaccines, RNA vaccines, inactivated virus vaccines, adenovirus-based vaccines, recombinant/ subunit protein vaccines, peptide vaccines, and virus-like particles etc. Inactivated virus vaccines and mRNA, and adenovirus-based vaccines have moved fast into clinical trials.<h4>Conclusion</h4>Vaccines containing spike protein of SARS-CoV as subunit could effectively prevent binding of coronavirus to the host cell and membrane fusion. Thus, spike protein can be used as a major target for subunit vaccine preparation.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Bentham Science Publishers Ltd.
dc.relation.ispartof	Recent patents on nanotechnology
dc.relation.isbasedon	10.2174/1872210515666210720130736
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0910 Manufacturing Engineering, 1007 Nanotechnology
dc.subject.classification	Nanoscience & Nanotechnology
dc.title	Nanovaccine: A hope to triumph the battle against novel Coronavirus disease 2019 (COVID-19).
dc.type	Journal Article
utslib.citation.volume	15
utslib.location.activity	United Arab Emirates
utslib.for	0910 Manufacturing Engineering
utslib.for	1007 Nanotechnology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2021-09-19T03:04:44Z
pubs.publication-status	Published
pubs.volume	15

Abstract:

Background

The novel coronavirus 2019 (COVID-19) infection has caused the global emergence of coronavirus in humans during the last 12 months. Till May 11, 2021, the confirmed global COVID-19 cases and deaths reached 158551526 and 3296855, respectively.

Methods

Goblet cells and ciliated cells in the nose act as the initial infection site of SARS-CoV-2. Thus, mucus immunity is important to protect from infection. The outburst of SARS-CoV-2 infection can be halted only when an effective vaccine will be developed.

Results

Globally, over 100 different vaccines are under investigation, including DNA vaccines, RNA vaccines, inactivated virus vaccines, adenovirus-based vaccines, recombinant/ subunit protein vaccines, peptide vaccines, and virus-like particles etc. Inactivated virus vaccines and mRNA, and adenovirus-based vaccines have moved fast into clinical trials.

Conclusion

Vaccines containing spike protein of SARS-CoV as subunit could effectively prevent binding of coronavirus to the host cell and membrane fusion. Thus, spike protein can be used as a major target for subunit vaccine preparation.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/150634